16867-35-9

Basic information

• Product Name: 2-(CHLOROMETHYL)-4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE
• Synonyms: Albb-006642;2-(chloromethyl)-4H-pyrido[1,2-a]pyrimidin-4-one(SALTDATA: FREE);2-ChloroMethyl-pyrido[1,2-a]pyriMidin-4-one;4H-Pyrido[1,2-a]pyriMidin-4-one,2-(chloroMethyl)-;2-(chloromethyl)-4-pyrido[2,1-b]pyrimidinone;2-(chloromethyl)pyrido[2,1-b]pyrimidin-4-one
• CAS NO: 16867-35-9
• Molecular Formula: C₉H₇ClN₂O
• Molecular Weight: 194.62
• Mol File: 16867-35-9.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 319.2 °C at 760 mmHg
• Flash Point: 146.8 °C
• Appearance: /
• Density: 1.36g/cm³
• Vapor Pressure: 0.000344mmHg at 25°C
• Refractive Index: 1.64
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 2-(CHLOROMETHYL)-4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(CHLOROMETHYL)-4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE(16867-35-9)
• EPA Substance Registry System: 2-(CHLOROMETHYL)-4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE(16867-35-9)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 16867-35-9(Hazardous Substances Data)

Usage

Uses

2-(Chloromethyl)-4h-pyrido[1,2-a]pyrimidin-4-one is a reactant used in the preparation of aminopiperidine quinolines and their azaisosteric analogs for their antibacterial activity.

InChI:InChI=1/C9H7ClN2O/c10-6-7-5-9(13)12-4-2-1-3-8(12)11-7/h1-5H,6H2

Upstream product

• 504-29-0 2-aminopyridine 
• 638-07-3 ethyl (2-chloroaceto)acetate 
• 32807-28-6 Methyl 4-chloroacetoacetate 

Downstream Products

• 951225-75-5 2-((4-(2-fluorophenyl)piperazin-1-yl)methyl)-4H-pyrido[1,2-a]pyrimidin-4-one 

Relevant articles and documents

Solvent-free synthesis of 4H-Pyrido[1,2-a]pyrimidin-4-ones catalyzed by BiCl3: A green route to a privileged backbone

An extensive array of 4H-pyrido[1,2-a]pyrimidin-4-ones have been synthesized from commercially available 2-aminopyridines and β-oxo esters with excellent yields under solvent-free conditions. The reaction, catalyzed by cheap and nontoxic BiCl3,

HETEROCYCLIC COMPOUNDS AND THEIR USES

Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110 activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia ( T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.

PYRIDINO[1,2-A]PYRIMIDIN-4-ONE COMPOUNDS AS ANTICANCER AGENTS

Pyridino[1,2-a]pyrimidinyl compounds, pharmaceutically acceptable salts, and prodrugs thereof; compositions that include a pharmaceutically acceptable carrier and one or more of the pyridino[1,2-a]pyrimidinyl compounds, either alone or in combination with